Panel Discussion: Overcoming Clinical Bottlenecks in LNP Development by Streamlining Processes for Advancing Safer Drug Products to Patients
- What are the greatest technical challenges in translating LNP formulations from preclinic to human studies?
- Given the complexity of LNP manufacturing, scale-up, and analytical characterization, what are the critical process and regulatory bottlenecks that currently slow clinical entry?
- How can developers prioritize indications, optimize clinical trial design, and build CMC readiness to ensure more programs successfully reach patients?